Murray Stahl's PACB Position Overview
Murray Stahl (via Horizon Kinetics Asset Management LLC) currently holds 10,551 shares of Pacific Biosciences of California, Inc. (PACB) worth $13,927, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 52 quarters.
Based on 13F filings since 2013, Murray Stahl has maintained a long-term strategic position in PACB, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2024, adding 483 shares. Largest reduction occurred in Q4 2023, reducing 483 shares.
Analysis based on 13F filings available since 2013 Q2
Murray Stahl's Pacific Biosciences of California (PACB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pacific Biosciences of California (PACB) Trades by Murray Stahl
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -483 | Reduce 4.38% | 10,551 | $1.32 |
| Q4 2025 | -483 | Reduce 4.19% | 11,034 | $1.87 |
| Q3 2025 | +483 | Add 4.38% | 11,517 | $1.28 |
| Q2 2025 | -483 | Reduce 4.19% | 11,034 | $1.24 |
| Q4 2024 | +483 | Add 4.38% | 11,517 | $1.83 |
| Q3 2024 | -483 | Reduce 4.19% | 11,034 | $1.70 |
| Q4 2023 | -483 | Reduce 4.03% | 11,517 | $9.81 |
| Q2 2013 | +12,001 | Add 0.00% | 12,000 | $2.50 |
Murray Stahl's Pacific Biosciences of California Investment FAQs
Murray Stahl first purchased Pacific Biosciences of California, Inc. (PACB) in Q2 2013, acquiring 12,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Murray Stahl has held Pacific Biosciences of California, Inc. (PACB) for 52 quarters since Q2 2013.
Murray Stahl's largest addition to Pacific Biosciences of California, Inc. (PACB) was in Q2 2013, adding 12,000 shares worth $30,000.
According to the latest 13F filing for Q1 2026, Murray Stahl's firm, Horizon Kinetics Asset Management LLC, owns 10,551 shares of Pacific Biosciences of California, Inc. (PACB), valued at approximately $13,927.
As of the Q1 2026 filing, Pacific Biosciences of California, Inc. (PACB) represents approximately 0.00% of Murray Stahl's publicly disclosed stock portfolio, making it one of their key holdings.
Murray Stahl's peak holding in Pacific Biosciences of California, Inc. (PACB) was 12,000 shares, as reported at the end of Q2 2013.